Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium being held January 15-17, 2021.
The presentations will cover the use of Guardant Health’s liquid biopsy technology to screen patients for colorectal cancer through to treatment for advanced disease.
"It is increasingly becoming evident that the value of our liquid biopsy in advanced cancer extends beyond simply tumor mutation profiling. The data presented further demonstrates the value of assessing molecular response to treatment, ushering in a new age of adaptive management of disease progression," said Helmy Eltoukhy, Guardant Health CEO. "Additionally, it is exciting to share advances being made with our Guardant Reveal™ blood test. This new offering will enable oncologists to improve the care of early-stage cancer patients by identifying high-risk patients that will benefit from adjuvant treatment and by detecting recurrent disease months earlier than current standard of care methods. We also look forward to sharing progress being made with our LUNAR-2 registrational grade ECLIPSE trial for the early detection of colorectal cancer in average-risk adults."
Data being presented:
Clinical utility of Guardant360® and GuardantOMNI® to detect clinically actionable mutations, tumor mutational burden, and molecular response (changes in circulating tumor DNA [ctDNA] associated with treatment effect) in metastatic colon, colorectal, and ductal adenocarcinoma cancers. (Abstracts: #61, #119, #423)
Status of the COBRA (NCT04068103) interventional study using the new Guardant Reveal™ liquid biopsy for ctDNA informed adjuvant therapy in resectable stage II colon cancer. Guardant Reveal is the first blood-only liquid biopsy for residual disease detection and recurrence monitoring. The company expects to make Guardant Reveal commercially available in Q1 2021. (Abstract: TPS #148)
Progress of the LUNAR-2 10,000 patient prospective study, ECLIPSE (NCT #04136002), which is expected to complete enrollment in 2021. The regulatory grade study is designed to evaluate the performance of LUNAR-2 to detect colorectal cancer in average-risk adults compared to screening colonoscopy. (Abstract: TPS #142)
Value of GuardantINFORM™ real-world clinical-genomic platform in enabling detailed outcomes research to accelerate the development of targeted cancer therapeutics for advanced colorectal cancer. Guardant Health and its collaborators explored the genomic landscape of these cancers, examined the heterogeneity of treatment regimens (both before and after comprehensive genomic profiling with Guardant360) and demonstrated the ability to examine associated clinical outcomes for these patients. (Abstract: #39)
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early-stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, including Guardant Reveal, as well as its clinical-genomic platforms and dataset, including GuardantINFORM, and the expected timeline for completing any clinical trials, including the ECLIPSE trial, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2019, in its Quarterly Reports on Form 10-Q for the periods ended March 31, 2020, June 30, 2020, and September 30, 2020, respectively, and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Source: Guardant Health, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005327/en/